|Over a week ago|
Veritiv announces $25M stock repurchase plan » 16:0003/1603/16/20
Veritiv announced that…
Veritiv announced that its Board of Directors has authorized a $25M stock repurchase program.
|Over a month ago|
Veritiv upgraded to Buy from Neutral at BofA » 06:0903/0603/06/20
BofA analyst John Babcock…
BofA analyst John Babcock upgraded Veritiv to Buy from Neutral with a price target of $16, down from $23. The analyst notes that the stock offers an "attractive" free cash flow and believes that any risks to its FY20 adj. EBITDA guidance are already reflected in its valuation.
Veritiv upgraded to Buy from Neutral at BofA » 06:0503/0603/06/20
BofA upgraded Veritiv to…
BofA upgraded Veritiv to Buy from Neutral.
Veritiv falls -14.8% » 12:0003/0503/05/20
Veritiv is down -14.8%,…
Veritiv is down -14.8%, or -$1.50 to $8.61.
|Over a quarter ago|
Fly Intel: Pre-market Movers » 09:1505/1305/13/19
TEVA, MYL, AMBR, SHLX, UBER, WFT, VRTV
HIGHER: Amber Road…
HIGHER: Amber Road (AMBR), up 27% after E2open announced a deal to acquire the company in an all-cash transaction valued at approximately $425M... Shell Midstream (SHLX), up 6% after entering into an agreement to acquire Shell's 25.97% equity interest in Explorer Pipeline and 10.13% equity interest in Colonial Pipeline for $800M. LOWER: Uber (UBER), down 7% in its second day of trading after its disappointing IPO on Friday... Weatherford (WFT), down 58% after announcing plans to restructure through a Chapter 11 bankruptcy filing... Veritiv (VRTV), down 3% after BofA/Merrill analyst John Babcock downgraded the stock to Neutral from Buy and lowered its price target to $26 from $37... Teva (TEVA) and Mylan (MYL), down 10% and 3%, respectively, after Connecticut Attorney General William Tong led a 44-state coalition in announcing a lawsuit against Teva and 19 other generic drug manufacturers alleging a "broad conspiracy to artificially inflate and manipulate prices, reduce competition and unreasonably restrain trade for more than 100 different generic drugs."
Veritiv downgraded to Neutral at BofA/Merrill » 07:3605/1305/13/19
As previously reported,…
As previously reported, BofA/Merrill analyst John Babcock downgraded Veritiv to Neutral from Buy and lowered its price target to $26 from $37. The analyst cut estimates to the low-end of the reduced adjusted EBITDA guidance range of $165M-180M, down from $190M-$200M, and sees limited catalysts to drive shares higher.
Veritiv downgraded to Neutral from Buy at BofA/Merrill 06:3405/1305/13/19
Veritiv lowers 2019 adjusted EBITDA view to $165M-$180M from $190M-$200M » 08:0905/0905/09/19
Expects to see a…
Expects to see a significant improvement in free cash flow for 2019 when compared to 2018, and, as a result, now expects free cash flow of at least $85M for the year, up from previous guidance of at least $55M.
Veritiv reports Q1 EPS ($1.68), consensus (71c) » 08:0805/0905/09/19
Reports Q1 revenue $1.9B,…
Reports Q1 revenue $1.9B, consensus $2.11B.